8 November 2024
Physiomics
plc
("Physiomics" or the
"Company")
Director
Dealing
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, announces that Dr Peter Sargent, Chief
Executive Officer and Director of the Company, has acquired, via
market purchases, 459,090 new ordinary shares of 0.4p in the
Company ("Ordinary Shares") at a price of 0.66p per Ordinary
Share.
Accordingly, Dr Sargent's total
holding in the Company will be 459,090 Ordinary Shares,
representing approximately 0.2% of the Company's issued share
capital and 4,064,175 performance rights under the Company's
existing share option schemes (with various vesting targets and
expiring on 5 February 2034).
Enquiries:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Limited (NOMAD)
James Dance & James
Bellman
+44 (0)20 7409 3494
PDMR Notification Form:
The notification below, which has
been made in accordance with the requirements of UK MAR, provides
further details.
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dr Peter Sargent
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chief Executive Officer and
Director
|
|
b)
|
Initial
notification/amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Physiomics plc
|
|
b)
|
LEI
|
213800A71DSZ6ABMTQ91
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv)each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Purchase of Ordinary
Shares
|
|
Identification code
|
GB00BDR6W943
|
|
b)
|
Nature of the Transaction
|
Purchase of new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.0066
|
459,090
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A (Single transaction)
|
|
e)
|
Date of the transaction
|
7 November 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
Notes to Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
